Funding opportunities

PUBLIC GRANTS, PUBLIC FUNDING INSTRUMENTS OR NON PROFIT COLLABORATIONS

 

Odoo image and text block

World: CARB-X, Combating Antibiotic Resistant Bacteria

SCOPE: CARB-X welcomes applications from around the world for funding and support for the early development of antibiotics, diagnostics, vaccines, devices and other products to combat the most serious drug-resistant bacteria.


KEY DATES & APPLICATION: CARB-X 2018 Funding Round 2 is now closed. The next round of funding will be announced in the coming months.

More information available here


NEWS:

May 22, 2018: UK GOVERNMENT AND BILL & MELINDA GATES FOUNDATION JOIN CARB-X PARTNERSHIP IN FIGHT AGAINST SUPERBUGS

 

Odoo image and text block

EU: InnovFin Infectious Diseases (IDFF)

SCOPEThe InnovFin Infectious Diseases Finance Facility (IDFF) provides financial products ranging from standard debt to equity-type financing for amounts typically between EUR 7.5 million and EUR 75 million, to innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases. Project costs may include clinical trial costs, set-up of commercialisation such as market access, development of prototypes or industrial roll-out of novel equipment, pre-clinical R&D costs and working capital requirement. The product is being made available directly through the European Investment Bank.

 

KEY DATES & APPLICATION: 
http://www.eib.org/en/products/blending/innovfin/how-to-apply/index.htm

More information available here 

Odoo image and text block

EU: Horizon2020 SME Instrument

SCOPEThe SME Instrument supports high-risk, high-potential small and medium-sized enterprises to develop and bring to market new products, services and business models that could drive economic growth. The SME Instrument is for innovators with ground-breaking concepts that could shape new markets or disrupt existing ones in Europe and worldwide. 

The SME Instrument provides full-cycle business innovation support. It has three phases, including a coaching service.

1. Feasibility study: Phase 1

2. From concept to market: Phase 2

3. Commercialisation: Phase 3


KEY DATES & APPLICATION: 
Opening date: 07 November 2017

Cut-off dates: Multiple (until oct/nov 2020)

More information available here 

Odoo image and text block

World: DRIVe BARDA initiative / DRIVe-X

SCOPEThe Biomedical Advanced Research and Development Authority (BARDA) serves the US nation by partnering with industry to make available medical countermeasures against wide range of major threats to the health security. DRIVe (Division of Research, Innovation, and Ventures) is a bold new approach to achieving once-unthinkable solutions to health security challenges – through the power of collaboration and innovation. DRIVe PPP will provide non-dilutive and dilutive funding opportunities to Companies (DRIVe-X), VCs (Ventures V), non-for-profit third parties (LAUNCH) and regional accelerators (ACCELERATORS). 3 Key focus Areas: 

> SEPSIS: new technologies to aid in restoring patients’ homeostasis. 

> ENACT (Early Notification to Act, Control and Treat): closing the gap between diagnosis and treatment by leveraging advanced data analytics and algorithms coupled with innovative detection modalities 

> Other areas: creating universal treatment options for broad classes of pathogens, ensuring access to life-saving medical countermeasures, and transforming medical countermeasure development by eradicating animal testing (non-exhaustive). 

More information available here

DRIVe EZ-BAA Notice details available here 

Odoo image and text block

EU: New IMI accelerator program for AMR-focused product development

SCOPEEU's IMI (Innovative Medicine Initiative) has initiated a new accelerator program for AMR-focused products. The goal of the AMR Accelerator is to provide one operational structure fostering a wide-ranging series of public-private partnership projects that will progress a pipeline of potential medicines and address some scientific challenges. The scope of the AMR accelerator is broad and tackles priority pathogens, including specific actions for Gram-negative bacteria, tuberculosis, and non-TB mycobacteria. Projects can encompass activities from testing of initial concepts up to completion of Phase 1 studies, and can include prophylaxis or treatment, antibiotics, or otherwise. Most of the current call focuses on partnership management and progression of compounds.

The programme is divided into 3 pillars:

> Pillar A, or Capability-Building Network, will be a consortium to coordinate the whole programme and to carry out research to strengthen the scientific basis in the AMR field by addressing pre-competitive challenges, with an initial focus on the use of animal models of infection and on sharing lessons learned from clinical trials.

> Pillar B, or Tuberculosis Drug Development Network, will be a consortium to accelerate the discovery of new drugs to treat TB and to collaboratively progress a portfolio of compounds contributed by EFPIA members and three associated partners (TBDA, BMGF, and University of Dundee).

> Pillar C, or Portfolio-Building Networks, will be a series of smaller partnerships, each with a single EFPIA partner and with a goal of accelerating the development of compounds for Gram-negative bacteria, tuberculosis, or non-TB mycobacteria.


KEY DATES & APPLICATION: 
Submission deadline: 24 October 2018 

More information available here

Odoo image and text block

World: The Bill & Melinda Gates Foundation Grand Challenges

SCOPEGrand Challenges is a family of initiatives fostering innovation to solve key global health and development problems. Each initiative is an experiment in the use of challenges to focus innovation on making an impact. Individual challenges address some of the same problems, but from differing perspectives. 

More information available here

Odoo image and text block

EU: Joint Programming Initiative on Antimicrobial Resistance (JPIAMR)

SCOPEJPIAMR supports research projects and networks that enable researchers to collaborate across national and scientific borders to tackle the global challenge of antimicrobial resistance. JPIAMR is a unique global collaborative platform that coordinates national funding and research to address antimicrobial resistance. The shared Strategic Research Agenda with a One Health perspective provides guidance for nations to align their AMR research nationally and internationally. To date, the 27 nations of JPIAMR have supported AMR research with funding of 65 million euro. 

More information available here

Odoo image and text block

World: European & Developing Countries Clinical Trials Partnership (EDCTP)

SCOPEThe European & Developing Countries Clinical Trials Partnership (EDCTP) funds clinical research to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials. EDCTP supports all phases of clinical trials, as well as product-focused implementation research, with a focus on phase II and III clinical trials, for new or improved medical intervention against poverty-related infectious diseases, including advanced testing and field validation of new diagnostic tools. EDCTP awards funding to collaborative clinical research projects conducted in sub-Saharan Africa on poverty-related infectious diseases, based on open, competitive and independently reviewed calls for proposals.

The EDCTP2 programme is supported under Horizon 2020, the European Union’s Framework Programme for Research & Innovation. 

More information available here

Odoo image and text block

EU: Partnering with AMR Centre (UK)

SCOPEAMR Centre accelerates the development of new antimicrobial drugs and diagnostics. As such the AMR Centre works globally with companies and research institutions to provide practical support and funding to help the development of their products from lead optimization through to Phase 2. The AMR Centre aims to progress up to 5 new projects each year under co-development and revenue sharing agreements.


KEY DATES & APPLICATION: Continuous application.

More information available here

Odoo image and text block

World: Global Antibiotic Research & Development Partnership (GARDP)

SCOPEGARDP works largely as a virtual R&D initiative through direct partnerships and multi-stakeholder collaborations, including with academia, industry, international organizations and governments.  GARDP develops partnership models tailored to the capacity and ability of actors involved: in certain programmes, GARDP will need to be actively driving and implementing R&D programmes, while in others, equitable partnerships will be sought whereby GARDP brings in the appropriate amount of funding, direction, and support. All GARDP funding are linked to the need to develop and make available affordable products that answer to public health needs.


KEY DATES & APPLICATION: Continuous.

More information available here


NEWS: 

May 22, 2018: GARDP’s efforts for drug-resistant gonorrhoea treatment receive boost from UK government

Odoo image and text block

EU: NAPD Vouchers Financing Instrument (The Netherlands)

SCOPEThe Netherlands Antibiotic Development Platform (NADP) has launched a novel funding opportunity during the NADP Voucher Event on 22 May 2018 in Utrecht, The Netherlands. The NADP Vouchers support early stage R&D on novel antibiotics and alternative approaches. There are 3 types of NADP Vouchers: 

1. Intellectual Property Vouchers - The compensation for the advice and assistance project can be maximally 5,000 euro, corresponding up to 75% of the total project costs. 

2. Value Proposition Vouchers - The compensation for the advice and assistance project can be maximally 15,000 euro, corresponding up to 75% of the total project costs. 

3. Lead Development Vouchers - The compensation for the advice and assistance project can be maximally 50,000 euro, corresponding up to 75% of the total project costs. 

Overall budget of EUR 450,000 to be distributed on the period 2018-2020 via those vouchers.  Vouchers can ONLY be applied by entities based in the Netherlands.


KEY DATES & APPLICATION: Applications can be submitted throughout the year, on a first come, first served basis. The collection dates for applications are:

> IP and Value Proposition Vouchers

- 01/09/2018 and 01/11/2018

- 01/02/2019, 01/04/2019, 01/06/2019, 01/08/2019 and 01/10/2019

> Lead Development Vouchers

- 01/09/2018

- 01/02/2019, 01/06/2019 and 01/10/2019. 

More information available here

INVESTORS

Odoo image and text block

World: Novo REPAIR Impact fund

SCOPE: The REPAIR (Replenishing and Enabling the Pipeline for Anti-Infective Resistance) Impact Fund will invest in start-ups, early-stage companies and corporate spin-outs in Europe and the United States. Their philosophy is to support ambitious programmes addressing antimicrobial resistance through a broad range of therapeutic modalities. The fund will focus on priority pathogens as defined by the World Health Organization and the United States Centers for Disease Control and Prevention, a catalogue of 12 families of bacteria that pose the greatest threat to human health. The fund is expected to invest USD 20 million to 40 million per year over 3–5 years in about 20 projects in Europe and the United States, which is anticipated to yield at least one new therapy reaching the market.

KEY DATES & APPLICATION: The first round of investments dedicated to European companies will start in April 2018 and non-confidential presentations can be sent until 15 May 2018. The first investments are expected by the end of 2018. A second round of investments focusing on United States companies will start in the fall 2018. Novo's REPAIR Impact fund will re-open for proposals during the window 4 Sep - 11 Oct.

More information available here